35/44
4.0 / 5 stars
All 44 Win/Lose results and 76 gray no-data contests shown below
MIRM Roast Me summary
Mirum Pharmaceuticals, Inc. (MIRM). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
Trailing 1 year (4 quarters): 8 wins, 0 losses, 4 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinMIRM / S&P 26.73% / 15.20% |
WinMIRM / S&P 44.02% / 15.00% |
No dataMIRM / S&P / 50.40% |
| 2026-Q12/2 |
WinMIRM / S&P 16.95% / -4.33% |
WinMIRM / S&P 50.19% / 11.30% |
No dataMIRM / S&P / 27.70% |
| 2025-Q42/2 |
WinMIRM / S&P 7.75% / 2.65% |
WinMIRM / S&P 54.74% / 9.00% |
No dataMIRM / S&P / 13.40% |
| 2025-Q32/2 |
WinMIRM / S&P 44.06% / 8.12% |
WinMIRM / S&P 53.66% / 4.61% |
No dataMIRM / S&P / 13.45% |
| 2025-Q22/2 |
WinMIRM / S&P 12.96% / 10.94% |
WinMIRM / S&P 62.33% / 4.83% |
No dataMIRM / S&P / 10.63% |
| 2025-Q12/2 |
WinMIRM / S&P 8.95% / -4.27% |
WinMIRM / S&P 69.31% / 4.98% |
No dataMIRM / S&P / 10.57% |
| 2024-Q42/2 |
WinMIRM / S&P 6.03% / 2.41% |
WinMIRM / S&P 80.76% / 5.25% |
No dataMIRM / S&P / 6.15% |
| 2024-Q32/2 |
WinMIRM / S&P 14.07% / 5.89% |
WinMIRM / S&P 112.14% / 5.89% |
No dataMIRM / S&P / 6.11% |
| 2024-Q22/2 |
WinMIRM / S&P 36.11% / 4.28% |
WinMIRM / S&P 128.34% / 5.38% |
No dataMIRM / S&P / 5.12% |
| 2024-Q11/2 |
LoseMIRM / S&P -14.91% / 10.56% |
WinMIRM / S&P 133.90% / 5.71% |
No dataMIRM / S&P / 5.59% |
| 2023-Q41/2 |
LoseMIRM / S&P -6.58% / 11.69% |
WinMIRM / S&P 141.85% / 6.81% |
No dataMIRM / S&P / 7.78% |
| 2023-Q32/2 |
WinMIRM / S&P 22.15% / -3.27% |
WinMIRM / S&P 176.75% / 7.52% |
No dataMIRM / S&P / -5.03% |
| 2023-Q21/2 |
LoseMIRM / S&P 7.70% / 8.74% |
WinMIRM / S&P 200.62% / 9.50% |
No dataMIRM / S&P / -8.57% |
| 2023-Q12/2 |
WinMIRM / S&P 23.18% / 7.50% |
WinMIRM / S&P 198.99% / 10.77% |
No dataMIRM / S&P / -15.69% |
| 2022-Q41/2 |
LoseMIRM / S&P -7.19% / 7.56% |
WinMIRM / S&P 302.66% / 11.88% |
No dataMIRM / S&P / -17.99% |
| 2022-Q32/2 |
WinMIRM / S&P 7.97% / -4.88% |
WinMIRM / S&P 226.84% / 13.47% |
No dataMIRM / S&P / -1.41% |
| 2022-Q22/2 |
WinMIRM / S&P -11.63% / -16.10% |
WinMIRM / S&P 250.13% / 13.71% |
No dataMIRM / S&P / 11.04% |
| 2022-Q11/1 |
WinMIRM / S&P 38.06% / -4.60% |
No dataMIRM / S&P / 15.97% |
No dataMIRM / S&P / 42.23% |
| 2021-Q40/1 |
LoseMIRM / S&P -19.93% / 11.03% |
No dataMIRM / S&P / 15.00% |
No dataMIRM / S&P / 96.40% |
| 2021-Q31/1 |
WinMIRM / S&P 15.21% / 0.58% |
No dataMIRM / S&P / 10.77% |
No dataMIRM / S&P / 69.42% |
| 2021-Q20/1 |
LoseMIRM / S&P -12.76% / 8.55% |
No dataMIRM / S&P / 6.58% |
No dataMIRM / S&P / 51.81% |
| 2021-Q11/1 |
WinMIRM / S&P 13.52% / 6.17% |
No dataMIRM / S&P / -1.06% |
No dataMIRM / S&P / 7.39% |
| 2020-Q40/1 |
LoseMIRM / S&P -9.39% / 12.15% |
No dataMIRM / S&P / -3.72% |
No dataMIRM / S&P / -33.42% |
| 2020-Q30/1 |
LoseMIRM / S&P -0.98% / 8.93% |
No dataMIRM / S&P / -2.04% |
No dataMIRM / S&P / -27.10% |
| 2020-Q21/1 |
WinMIRM / S&P 39.00% / 20.54% |
No dataMIRM / S&P / -0.46% |
No dataMIRM / S&P / -27.11% |
| 2020-Q10/1 |
LoseMIRM / S&P -42.90% / -19.60% |
No dataMIRM / S&P / 3.47% |
No dataMIRM / S&P / -14.75% |
| 2019-Q41/1 |
WinMIRM / S&P 143.74% / 9.07% |
No dataMIRM / S&P / 5.36% |
No dataMIRM / S&P / 2.99% |
| 2019-Q30/0 |
No dataMIRM / S&P / 1.70% |
No dataMIRM / S&P / 5.02% |
No dataMIRM / S&P / 0.21% |
| 2019-Q20/0 |
No dataMIRM / S&P / 4.30% |
No dataMIRM / S&P / 6.64% |
No dataMIRM / S&P / 8.65% |
| 2019-Q10/0 |
No dataMIRM / S&P / 13.65% |
No dataMIRM / S&P / 8.12% |
No dataMIRM / S&P / 14.29% |
| 2018-Q40/0 |
No dataMIRM / S&P / -13.52% |
No dataMIRM / S&P / 9.05% |
No dataMIRM / S&P / 18.23% |
| 2018-Q30/0 |
No dataMIRM / S&P / 7.71% |
No dataMIRM / S&P / 10.21% |
No dataMIRM / S&P / 19.06% |
| 2018-Q20/0 |
No dataMIRM / S&P / 3.43% |
No dataMIRM / S&P / 9.03% |
No dataMIRM / S&P / 14.46% |
| 2018-Q10/0 |
No dataMIRM / S&P / -0.76% |
No dataMIRM / S&P / 7.68% |
No dataMIRM / S&P / 12.46% |
| 2017-Q40/0 |
No dataMIRM / S&P / 6.64% |
No dataMIRM / S&P / 7.03% |
No dataMIRM / S&P / 13.82% |
| 2017-Q30/0 |
No dataMIRM / S&P / 4.48% |
No dataMIRM / S&P / 5.68% |
No dataMIRM / S&P / 17.57% |
| 2017-Q20/0 |
No dataMIRM / S&P / 3.09% |
No dataMIRM / S&P / 4.83% |
No dataMIRM / S&P / 17.74% |
| 2017-Q10/0 |
No dataMIRM / S&P / 6.07% |
No dataMIRM / S&P / 3.67% |
No dataMIRM / S&P / 13.32% |
| 2016-Q40/0 |
No dataMIRM / S&P / 3.82% |
No dataMIRM / S&P / 2.09% |
No dataMIRM / S&P / 7.05% |
| 2016-Q30/0 |
No dataMIRM / S&P / 3.85% |
No dataMIRM / S&P / 0.20% |
No dataMIRM / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | MIRM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 31.96% | 20.78% |
| Annualized return | 31.96% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | MIRM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 502.46% | 83.14% |
| Annualized return | 43.21% | 12.86% |
10Y · 2019-07-18 to 2026-08-28
| Metric | MIRM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 637.91% | 319.30% |
| Annualized return | 22.12% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |